Axolabs: LGC Snaps Up Axolabs, Adding to TNA Capabilities

LGC said today it has acquired Axolabs, a contract research, development and manufacturing organization (CDMO) focused on developing therapeutic nucleic acids (TNAs), for an undisclosed price. LGC also said it is carrying out a "major investment," also undisclosed, at its Biosearch subsidiary in Petaluma, CA. The investment will expand the company's GMP oligonucleotide manufacturing capacity in order to provide TNA synthesis to the 1kg scale in support of early stage clinical trials. LGC said the acquisition and investment will position the company as a global provider of TNA solutions, as well as strengthen its existing analytical and bioanalytical drug development service offering, as customers will be able to access integrated analytical and manufacturing solutions from lead discovery through clinical phases and beyond. Based in Kulmbach, Germany, Axolabs specializes in discovery and pre-clinical phases of drug development in the field of oligonucleotide therapeutic and other nucleic acid medicines. ...